Carmell Therapeutics Corporation
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Rajiv Sarman Shukla
- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2403 Sidney Street Pittsburgh PA United States of America 15203
- IPO Date
- Sep 23, 2021
- CIK
- 0001842939
- Website
- carmellrx.com
- Similar Companies
- Business
- Carmell Corporation Carmell Corporation (Nasdaq: CTCX), formerly Carmell Therapeutics Corporation, operates as a bio-aesthetics company focused on skin and hair health utilizing its proprietary Carmell Secretome technology, a potent cocktail of growth factors and proteins extracted from allogeneic human platelets sourced from FDA-approved tissue banks; the company develops and commercializes microemulsion formulations that deliver lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients commonly used in cosmetics for texture and stability; its product portfolio includes physician-dispensed skincare and haircare applications such as topical haircare products, men's grooming lines, and exosome-based skin rejuvenation solutions acquired from Elevai Skincare; additionally, Carmell leverages plasma-based bioactive materials (PBM) for regenerative applications in orthopedics, wound care, bone healing accelerants for tibia fractures, foot/ankle fusion, spinal fusion, dental bone grafts, and soft tissue repair. Headquartered in Pittsburgh, Pennsylvania, the company was founded in 2008 and maintains operations primarily in the United States, targeting professional care providers, physicians, and retail consumers in the aesthetics, dermatology, and regenerative medicine sectors; it holds a licensing agreement with Carnegie Mellon University for biocompatible plasma-based plastics and previously merged with Axolotl Biologix in 2023 to expand into profitable regenerative products for soft tissue repair, aesthetics, and orthopedics. Recent developments include the January 2025 closing of the Elevai Skincare acquisition, adding a revenue-generating product portfolio with FY2024 sales of approximately $2.5 million, commercial team, $1.0 million in inventory, and exosome technology for skin and hair care, structured with $1.1 million in stock, cash payments, and earnouts tied to future sales milestones; in late 2024, Carmell completed a $1.85 million PIPE investment from existing and new investors to support commercial build-out, issuing shares and warrants; the company rebranded to emphasize longevity health strategies in early 2025 and announced plans for mergers like THPlasma to diversify into plasma operations while advancing clinical trials such as HEAL II for bone healing.
Comparing Carmell (NASDAQ:CTCX) and Acutus Medical (NASDAQ:AFIB)
Reviewing Carmell (NASDAQ:CTCX) and SANUWAVE Health (OTCMKTS:SNWV)
Head-To-Head Comparison: Carmell (CTCX) vs. Its Rivals
CARMELL CORP REBRANDS AS LONGEVITY HEALTH HOLDINGS TO HIGHLIGHT BUSINESS FOCUS & GROWTH STRATEGY
Carmell Announces Closing of Elevai Skincare Acquisition
Carmell Announces Closing of Previously Announced PIPE Investment from Existing and New Investors to Support Commercial Build-out
Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products
Carmell Announces PIPE Investment From Existing and New Investors To Support Commercial Build-out
Carmell Corporation Appoints New CEO Following Addition to the Russell Microcap Index
Carmell Announces Successful Closing of $3.0 Million Private Placement
Carmell Announces $3.0 Million Private Placement
Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction
Carmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix Subsidiary
Carmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics Field
Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024
Carmell Corp Announces Addition of Scott Frisch and Gilles Spenlehauer to Board of Directors
Moonshot Client Axolotl Announces Merger with Carmell Therapeutics, Elevating the Field of Regenerative Medicine
Carmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organizational Structure Aligned with Focus on Aesthetics
Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity
Best Penny Stocks To Buy? 6 To Watch Before Next Week